InvestorsObserver
Sign Up Login

VIVE Viveve Medical

$0.99 $0.03 (2.60%)
Add to Watchlist Compare
Overall

VIVE Stock Analysis Overview

What this means: InvestorsObserver gives Viveve Medical (VIVE) an overall rank of 44, which is below average. Viveve Medical is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 44 means that 56% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

VIVE Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

VIVE Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

VIVE Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

VIVE Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

VIVE Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

VIVE Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

VIVE Stock Analysis Overview

What this means: InvestorsObserver gives Viveve Medical (VIVE) an overall rank of 44, which is below average. Viveve Medical is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 44 means that 56% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full VIVE report

VIVE Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

VIVE Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

VIVE Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

VIVE Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

VIVE Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

VIVE Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Viveve Medical (VIVE) Analyst Forecast

VIVE Price, Volume, Earnings, and Dividend Date

  • Last Price $0.99
  • Previous Close $0.97
  • Change $0.03
  • Open $0.97
  • Volume 69,163
  • Avg. Volume (100-day) 328,981
  • Market Cap 10,497,595
  • Days Range 0.97 - 1.04
  • 52-week Range 0.88 - 5.4
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 02/10/22
  • Sector Healthcare
  • Industry Medical Devices
  • Avg. Analyst Rec. Premium
  • Beta 1.243
  • PEG Ratio —

Viveve Medical (VIVE) Company Description

Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.

Viveve Medical (VIVE) Stock Chart

View Interactive VIVE chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Medical Devices

Company Price
Varex Imaging Corp (VREX) (VREX) $26.43
Biotricity Inc (BTCY) (BTCY) $2.82
Sensus Healthcare Inc (SRTS) (SRTS) $7.23
Electromed Inc (ELMD) (ELMD) $12.59
Livanova Plc OR Sh (LIVN) (LIVN) $74.28
Steris Corp (STE) (STE) $218.12
Cutera Inc (CUTR) (CUTR) $33.51
Remsleep Holdings Inc (RMSL) (RMSL) $0.02
Edwards Lifesciences Corp (EW) (EW) $108.63
Boston Scientific Corp (BSX) (BSX) $43.04